Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

NCT05193578 on ClinicalTrials.gov · last registry update 2024-07-08

Finished 18 March 2024, after enrolling 154 people. Primary outcome, as filed: HbA1c (mmol/mol). semaglutide is approved in the US, but not for prediabetes and psychiatric — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Jan Frystyk
Sponsor type: Other
Enrollment: 154
Started: 2022-01-01
Primary completion: 2024-03-18 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

HbA1c (mmol/mol)

Conditions studied

Schizophrenia · Prediabetic State

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.